+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Uptravi"

Cardiovascular Drugs: Global Markets to 2022 - Product Thumbnail Image

Cardiovascular Drugs: Global Markets to 2022

  • Report
  • March 2018
  • 174 Pages
  • Global
From
From
Disease Analysis: Pulmonary Hypertension - Product Thumbnail Image

Disease Analysis: Pulmonary Hypertension

  • Drug Pipelines
  • April 2021
  • 78 Pages
  • Global
Tyvaso - Product Thumbnail Image

Tyvaso

  • Report
  • October 2018
  • 17 Pages
  • Global
From
  • 6 Results (Page 1 of 1)
Loading Indicator

Uptravi (selexipag) is a medication used to treat pulmonary arterial hypertension (PAH). It is a prostacyclin receptor agonist, which works by relaxing the blood vessels in the lungs to improve blood flow. Uptravi is the first and only oral medication approved by the U.S. Food and Drug Administration (FDA) for the treatment of PAH. It is also approved in the European Union and other countries. The Uptravi market is a rapidly growing segment of the cardiovascular drugs market. It is estimated that the global PAH market will reach $4.5 billion by 2026, driven by the increasing prevalence of PAH and the introduction of new treatments. Uptravi is expected to be a major contributor to this growth. Companies in the Uptravi market include Actelion Pharmaceuticals, United Therapeutics Corporation, GlaxoSmithKline, Bayer AG, and Pfizer Inc. Show Less Read more